Smartkarma Corporate Webinar | New Horizon Health: A Case of Successful Commercialization
For our next Corporate Webinar we are glad to welcome New Horizon Health’s CFO, Yu Gao.
In the upcoming webinar, Mr Gao will share a short company presentation after which, he will engage in a fireside chat with Smartkarma Insight Provider, Ke Yan. The Corporate Webinar will include a live Q&A session.
The Corporate Webinar will be hosted on Tuesday, 21 February 2023, 17:00 SGT.
About New Horizon Health
New Horizon Health (6606 HK) is a biotech focusing on the research, development and commercialization of molecular diagnostics for cancer screening in China and globally. New Horizon Health currently has three NMPA approved cancer screening tests: ColoClear: the only colorectal cancer screening test approved by NMPA (Class III medical device) for high-risk colorectal cancer population in China; Pupu Tube: the only self-conducted FIT test approved by NMPA (Class II medical device) for average-risk colorectal cancer population in China. It also obtained CE Mark in 2018; and UU Tube: the only self-conducted H. Pylori diagnostic test approved by NMPA (Class III medical device) in China. It also obtained CE Mark in 2022. The company also has pipeline tests, as well as many other undisclosed cancer screening tests under research development.
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
